Cargando empresa
Just reported
Q3 2026 results
From Waters's results release of 3 de noviembre de 2026; its quarterly report has since been filed.
Revenue
Actual
1,77B US$
+121 % y/y
+7,4 % q/qGuided
858,5M US$
midpoint
Above guide+106 %EPS, GAAP
Actual
0,82 US$
-67 % y/y
Guided
—
No guide given
Operating income, GAAP
Actual
128M US$
-33 % y/y
Guided
—
No guide given
Company outlook
Full year 2026
- Revenue3,429B US$+8,3 % y/y Raised +1,8 %
- EPS, adjusted14,60 US$ – 14,70 US$Raised +1,4 %
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The full earnings report →Keep exploring
The themes Waters is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
The theme it is part of
Highest-graded in Diagnostics and Research
Graded A or B and worth $2B or more: A first, then the largest.
TMOThermo Fisher Scientific Inc.259,2B US$A+
IDXXIdexx Laboratories Inc.55B US$A+
IQVIQVIA Holdings Inc.44,7B US$A
ILMNIllumina, Inc.31,7B US$A+
LHLabcorp Holdings Inc.30,2B US$A
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 oct 2026CBGraded C, now B
MCKMckesson Corporation4 nov 2026BAGraded B, now A
CVSCVS Health Corp4 nov 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 nov 2026BAGraded B, now A
BIIBBiogen Inc.28 oct 2026BAGraded B, now A
Estados financieros completos →
Construido a partir de los propios informes de Waters Corporation ante la Comisión de Bolsa y Valores de EE. UU. (SEC). Las cifras son las declaradas, con el historial por acción reexpresado a la base de acciones de hoy. Esto describe un negocio: no es asesoramiento de inversión ni una recomendación de compra o venta.